2024 could be an eventful year for LUTATHERA and radioligand therapies (RLTs) around their future commercial prospects. On 23rd April 2024, the FDA approved LUTATHERA (also known as lutetium ...
Ipsen Partners with Skyhawk Therapeutics for RNA-Focused Research in Rare Neurological Disorders Ipsen and Skyhawk Therapeutics have entered into an exclusive global partnership to explore and create new small molecules that can influence RNA for rare neurological conditions. Under this agreement, Ipsen has the ...
Find More
Roche's Columvi Achieves Primary Endpoint of Prolonged Overall Survival in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Trial Roche reported that the Phase III STARGLO trial successfully achieved its main goal of improving overall survival. The research revealed that in...
Find More
ENHERTU lies at the core of AstraZeneca and Daiichi Sankyo’s objectives for advancing in oncology. This collaboration has notably broadened the antibody-drug conjugates impact in the United States. On April 5, 2024, the FDA approved ENHERTU to treat HER2-positive solid tumors in adults who have received previous sy...
Find More
Glioblastoma or Glioblastoma Multiforme (GBM) represents the most common primary tumor of the central nervous system (CNS). Despite advancements in diagnostic approaches and the development of new therapies, the prognosis for glioblastoma patients remains notably poor, with limited improvement observed. At AACR ...
Find More
The findings presented at the 2024 AACR conference revealed that among patients diagnosed with PIK3Ca-mutated MSS mCRC (n = 22), three patients attained a partial response (PR). Additionally, one more patient with PIK3Ca-mutated mCRC maintained stable disease (SD). The study successfully achieved its primary endpoi...
Find More
Melanoma, a type of skin cancer, poses a significant health concern globally. Advanced and metastatic stages of melanoma present particularly formidable challenges, often necessitating innovative treatment approaches to address their aggressive nature and high mortality rates. Patients with ICI-resistant metasta...
Find More
TG4050 is a neoantigenic cancer vaccine derived from Transgene's myvac platform and leverages NEC's Artificial Intelligence (AI) technologies to identify and predict the most potent neoantigens for immunogenicity. According to the data presented at the AACR 2024 conference, at a median follow-up duration of 18.6 mo...
Find More
The presentation by ALX Oncology at the AACR Annual Meeting 2024 provided promising insights into the efficacy and safety of their investigational drug, evorpacept, in combination with standard rituximab and lenalidomide for patients with relapsed or refractory B cell non-Hodgkin lymphoma (R/R B-NHL). The Phase ...
Find More
As per the data presented at the AACR 2024 conference, of the 21 patients who received AZD1390 in conjunction with radiation therapy at manageable doses, the median overall survival (OS) stood at 12.7 months. In arm A, comprising 75 patients with recurrent glioblastoma, the combination therapy of AZD1390 and IMR...
Find More
Real-world evidence (RWE) is used in an exponential way to guide payment decisions and access system.....
Find More-Feature.png)
Gastroesophageal Reflux Disease (GERD, also known as chronic acid reflux) is a digestive disorder in.....
Find More
Sepsis is a life-threatening organ dysfunction caused by dysregulated host response to infection. Se.....
Find More
There are about 200 different types of cancer, making it one of the most diverse types of indication.....
Find More
T cell Lymphoma (TCL) is cancer that develops in the T-lymphocytes. T-cell Lymphomas are majorly cla.....
Find More
Myasthenia Gravis is a chronic autoimmune neuromuscular disease responsible for weakness in the skel.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
